Palvella Therapeutics
PVLA
98 hedge funds and large institutions have $96.9M invested in Palvella Therapeutics in 2019 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 14 closing their positions.
127% more call options, than puts
Call options by funds: $693K | Put options by funds: $305K
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
5% more funds holding
Funds holding: 93 → 98 (+5)
0.02% more ownership
Funds ownership: 0.7% → 0.72% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 31
25% less capital invested
Capital invested by funds: $129M → $96.9M (-$31.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$7.29M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$6.75M |
| 3 |
BlackRock
New York
|
+$4.39M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.19M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$6.95M |
| 2 |
Millennium Management
New York
|
-$5.69M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$3.1M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.7M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$1.62M |
PVLA Hedge Fund Activity: Q3 2019 in Review
98 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2019, worth a combined $96.9M — down 25% from $129M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PVLA positions and 14 closed out — a net gain of 5 holders — while 27 added to existing stakes and 31 trimmed.
The largest buyer was Aquilo Capital Management, adding an estimated $7.29M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $6.95M sold.
- 98 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2019, up from 93 in Q2 2019.
- Funds reported $96.9M of Palvella Therapeutics stock for Q3 2019, down 25% quarter-over-quarter.
- 19 funds opened new Palvella Therapeutics positions in Q3 2019 and 14 closed out, a net change of +5 holders.
- The largest Palvella Therapeutics buyer in Q3 2019 was Aquilo Capital Management, an estimated $7.29M added.
- The largest Palvella Therapeutics seller in Q3 2019 was Nantahala Capital Management, an estimated $6.95M sold.
Based on aggregated 13F filings for Q3 2019.